Company profile · free preview
Procter & Gamble
PG · Updated 11/12/2026
Revenue
$87.0B
Fiscal 2026
Net income
$16.0B
Fiscal 2026
Free cash flow
$15.1B
Fiscal 2026
Net cash / (debt)
—
Fiscal 2026
Five-year financials
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $87.0B | $84.3B | $84.0B | $82.0B | $80.2B |
| Net income | $16.0B | $16.0B | $14.9B | $14.7B | $14.7B |
| Diluted EPS | — | — | — | — | — |
| Operating cash flow | $19.6B | $17.8B | $19.8B | $16.8B | $16.7B |
| Free cash flow | $15.1B | $14.0B | $16.5B | $13.8B | $13.6B |
| Cash | — | — | — | — | — |
| Total debt | — | — | — | — | — |
Financial trends
Historical · FY2022–FY2026
Source: Reported annual filings (10-K / 20-F) and provider data. Fiscal years as reported; margins are calculated from the reported figures shown.
Want the story behind these numbers? Ask Osiris anything about Procter & Gamble's filings — free.
Create free accountWhere the cash went
Cumulative, fiscal 2022–2026, straight from the reported cash-flow statements.
Reinvested in capex
19.5%
of operating cash flow
Returned to owners
—
of free cash flow (buybacks + dividends)
Diluted share count
—
change 2022–2026
| Operating cash flow | $90.8B |
| Capital expenditure | ($17.7B) |
| Free cash flow | $73.1B |
| Share buybacks | — |
| Dividends paid | — |
| Acquisitions (net) | — |
| Net debt issued / (repaid) | — |
| Stock-based compensation (non-cash) | — |
"—" means a year didn't report that line, so no total is shown rather than an estimate.
Procter & Gamble return on capital (fiscal 2026)
ROIC
17.5%
Return on capital
18.8%
Return on equity
30.1%
Return on assets
12.7%
Gross margin
50.2%
Operating margin
22.7%
Net debt / EBITDA
1.06x
Procter & Gamble insider buying and selling
Recent open-market trades reported on Form 4. Context only — not a reason to buy or sell.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-11-05 | Santos de Azevedo Juliana Monteiro | Sale | 5,370 | $169.00 |
| 2026-11-05 | Schulten Andre | Sale | 30,677 | $169.00 |
| 2026-11-04 | Schulten Andre | Sale | 33,624 | $165.00 |
| 2026-11-03 | Janzaruk Matthew W. | Sale | 9,479 | $163.00 |
| 2026-10-30 | Gama Paul | Sale | 2,894 | $165.00 |
SEC filings
No filings stored yet.
Ask anything about Procter & Gamble's filings
"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.
Start researching free